European drugmakers advanced this week after GlaxoSmithKline Plc, Europe's biggest pharmaceutical company, AstraZeneca Plc, the second largest, and Roche Holding AG raised sales and profit forecasts. \nCie de Saint-Gobain SA, the world's biggest glassmaker, and DSM NV, the largest maker of drug ingredients, paced the week's declines among some exporters as the dollar slipped 2.7 percent against the euro to its lowest in three weeks. \nOn Friday, the Dow Jones Stoxx 50 Index dropped 29.55, or 1.2 percent, to 2407.11, trimming its advance for the week to 0.1 percent. The Stoxx 600 declined 0.8 percent to 205.79, cutting the weekly gain to 0.3 percent. \nDrug companies led gains among the Stoxx 600's 18 industry groups. GlaxoSmithKline, Roche and AstraZeneca were among the top 10 performers on the Stoxx 50 after reporting profit that beat analysts' estimates because of sales growth and cost cuts. \n"It shows the darkest period is over for big pharmaceuticals for a while," said Youri Amerijckx, who manages US$460 million of healthcare stocks, including Roche Holding, at KBC Asset Management, Belgium's largest asset manager by market share. \nBefore this week, the Stoxx 600 Healthcare Index had dropped 1.8 percent in 2003, while the Stoxx 600 gained 1.7 percent. \nBenchmark indexes fell in 13 of the 17 Western European markets on Friday. Germany's DAX slipped 0.5 percent. The UK's FTSE 100 declined 0.4 percent, and France's CAC dropped 1.5 percent. \nSeptember futures on the Dow Jones Euro Stoxx 50 Index of companies based in the 12 countries sharing the euro shed 0.9 percent to 2452. The index dropped 1.6 percent to 2442.13. \nDrug companies \nGlaxoSmithKline was the fourth-best performer in the Stoxx 50 this week, climbing 4 percent. Europe's biggest drugmaker said Wednesday full-year earnings per share may exceed the "high single digit" growth it forecast in April. The shares slid 1.3 percent to UK Pound 12.15 on Friday. \nAstraZeneca, Europe's second-biggest drugmaker, climbed 2.6 percent this week. The company boosted its full-year outlook after second-quarter profit fell less than analysts expected. The stock dropped 0.6 percent on Friday to UK Pound 24.94. \nRoche, the world's biggest maker of cancer drugs, slipped 1.3 percent to 111.25 Swiss francs, for a 3 percent weekly gain. The company Wednesday raised the estimate for its Mabthera blood-cancer medicine to Sf4.5 billion (US$3.3 billion) and for Pegasys, a hepatitis C treatment, to Sf2 billion. \n"Drug developers provide defense against all the economic uncertainty out there and on top of that they are releasing good earnings: that makes them a good bet," said Miguel Angel Castro, who helps manage the equivalent of US$577 million at Renta 4 SA in Madrid, which recently bought AstraZeneca shares. \nDollar hurts some \nA declining dollar might outweigh any benefit to European companies from an expanding US economy, eroding earnings generated in the US and making their products more expensive. \nSaint-Gobain, founded in 1665 to produce mirrors in French King Louis XIV's palace in Versailles, slipped 1.8 percent to 33.10 euros, for a weekly slide of 4.2 percent. The company, whose products include perfume bottles and roof shingles, expects full-year profit to drop after first-half earnings fell 5.6 percent to 470 million euros (US$541 million). \nDSM sank 3.4 percent to 40.17 euros after saying third-quarter profit may drop more than 25 percent from 68 million euros in the second quarter. The shares gained 1.4 percent in the week. \nExchange rates \nRhodia SA, France's biggest specialty-chemicals maker, dropped 4.6 percent to 5.38 euros after saying the second half is proving more difficult than anticipated, partly because of changes in demand and foreign exchange rates. It posted a second-quarter net loss of 87 million euros, hurt by increased petrochemical prices. The stock lost 5.1 percent this week. \nSiemens, Germany's biggest electronics and engineering company, dropped 0.2 percent to 49.00 euros, trimming its gain for the week to 3.4 percent. The company said Thursday fiscal third-quarter net income fell 13 percent to 632 million euros, beating the 454 million-euro average estimate by analysts surveyed by Bloomberg News. \nRenault SA, France's No. 2 carmaker, climbed 3.8 percent to 49.8 euros. The company said first-half net income rose 32 percent to 1.18 billion euros, boosted by affiliate Nissan Motor Co, which almost tripled earnings. First-half net income beat the 1.1 billion-euro median forecast of 12 analysts surveyed by Bloomberg News. The stock added 3.8 percent this week. \nInsurers \nLegal & General Group Plc Thursday predicted sales of financial products will rise, lifting shares of UK rivals such as Prudential Plc, the country's largest insurer, and Aviva Plc. \nLegal & General, the UK's fourth-largest insurer, climbed 4.6 percent to UK Pound 0.97, bringing its weekly advance to 8.7 percent. \nThe company said it expects demand to improve in the second half. \nFirst-half operating profit rose 1 percent to UK Pound 365 million (US$587 million). Analysts surveyed by Bloomberg had expected profit of UK Pound 364 million. \nPrudential Plc, the largest UK insurer by premium income, climbed 1.6 percent to UK Pound 4.33, for a weekly gain of 3.3 percent. \nAviva Plc, the country's second-biggest insurer, added 1.7 percent to UK Pound 4.9725, for a 4.3 percent rise since last Friday. \nZeltia SA, a Spanish company developing cancer treatments from marine life, slumped 19 percent to 5.79 euros. The rejection of its most advanced drug, Yondelis, by the European Agency for the Evaluation of Medicinal Products raised concern about the company's ability to continue funding research. The stock fell 6.2 percent this week.
‘BIG LOSS’: This year might see the last generation of Huawei’s Kirin chips, as their production would stop next month because they are made using US technology Chinese tech giant Huawei Technologies Co (華為) is running out of processor chips to make smartphones due to US sanctions and would be forced to stop production of its own most advanced chips, a company executive has said, in a sign of growing damage to Huawei’s business from US pressure. Huawei, one of the biggest producers of smartphones and network equipment, is at the center of US-Chinese tension over technology and security. Washington last year cut off Huawei’s access to US components and technology, and those penalties were tightened in May, when the White House barred vendors worldwide from using US
’WHITE BOX’: The open platform would give local firms access to Cisco’s cloud-based mobile network to develop 5G telecom equipment and tap into the global market The Ministry of Economic Affairs (MOEA) yesterday introduced a new 5G “open lab” in collaboration with US-based information technology and networking giant Cisco Systems Inc to address the rapidly growing “white box” 5G networking equipment market. The open lab will be a platform where Taiwanese manufacturers can access Cisco’s cloud-based mobile network to develop their own 5G telecom equipment, such as small-cell base stations, network switches, modems and Internet of things (IoT) devices, a ministry statement said. The open platform would allow Taiwanese manufacturers to tap into the lucrative 5G telecom equipment market, which was previously monopolized by Nokia Oyj, Ericsson AB
Nintendo Co is raising its target for Switch production to about 25 million units this fiscal year, people familiar with the matter said, as the ongoing COVID-19 pandemic keeps lifting demand and component shortages ease. The Kyoto, Japan-based company, which in April hiked orders to 22 million units by March next year, is asking partners to tack on another few million units, said the people, who did not want to be identified discussing internal goals. Assembly partners plan to work at maximum capacity through December. The new production target suggests that Nintendo is likely to outperform its Switch sales forecast of 19 million
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reported that revenue last month expanded 25 percent annually, but fell 12.8 percent month-on-month to NT$105.96 billion (US$3.59 billion). In the first seven months of this year, the chipmaker’s revenue surged 33.6 percent to NT$727.26 billion, compared with NT$544.46 billion a year earlier. TSMC has said it aims to grow its revenue by more than 20 percent this year. The company has since May 15 stopped taking new orders from Huawei Technologies Co (華為), its second-biggest customer after Apple Inc, due to the US’ restrictions on exports containing US technologies. TSMC has no plans to